About: The Endothelial Dysfunction and Pyroptosis Driving the SARS-CoV-2 Immune-Thrombosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Endothelial Dysfunction and Pyroptosis Driving the SARS-CoV-2 Immune-Thrombosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The Endothelial Dysfunction and Pyroptosis Driving the SARS-CoV-2 Immune-Thrombosis
Creator	Paula, Ana Ribeiro, M De Noronha, Lucia Borges, Nicolas Dezidério, Felipe Flavia, Anna Godoy, Thiago Machado-Souza, Cleber Martins, C Mendes, Monalisa Nagashima, Seigo
source	MedRxiv
abstract	Objective: Endothelial activation after viral infection could contribute to changes in the vascular glycocalyx associated with programmed inflammatory cell death called pyroptosis. Thus, our goal is to recognize endothelial activation and pyroptosis in lung and myocardial samples of Coronavirus disease (COVID-19) cases and compare to H1N1pdm09 and control cases. Approach and Results: Post-mortem lung (6 cases of COVID-19 group; 10 cases of H1N1 group and 11 cases of Control group) and myocardial samples (2 cases of COVID-19 and one control) were analyzed by conventional immunohistochemistry by using antibodies to identify molecules involving with endothelial activation (CD163, Interleukin-6 (IL-6), Tumor Necrosis Factor alpha (TNF-alpha), Intercellular Adhesion Molecule 1 (ICAM-1)) and pyroptosis (Caspase-1). As a result, IL-6, TNF-alpha, ICAM-1, and Caspase-1 show higher tissue expression in the COVID-19 group compared to H1N1 and Control groups. Conclusion: Our results indicate that the vascular endothelium has been activated and the presence of pyroptosis and endothelial dysfunction in lung and myocardial samples. These conditions could lead to a systemic immune-thrombotic process that may impair the clinical staff's efforts to prevent fatal outcomes. One aim of the health professionals is to avoid COVID-19 systemic vascular injury and immune-thrombosis by blocking the endothelial dysfunction and its consequences.
has issue date	2020-06-19(xsd:dateTime)
bibo:doi	10.1101/2020.06.17.20133124
has license	medrxiv
sha1sum (hex)	9c70350fb6f7b6485b1714ab419f70196f502cc9
schema:url	https://doi.org/10.1101/2020.06.17.20133124
resource representing a document's title	The Endothelial Dysfunction and Pyroptosis Driving the SARS-CoV-2 Immune-Thrombosis
resource representing a document's body	covid:9c70350fb6f7b6485b1714ab419f70196f502cc9#body_text
is schema:about of	named entity 'Immune' named entity 'Dysfunction' named entity 'THROMBOSIS' named entity 'IMMUNE' named entity 'Pyroptosis' named entity 'macrophages' named entity 'endothelium' named entity 'COVID' named entity 'Intensive Care Unit' named entity 'H1N1' named entity 'edema' named entity 'H1N1' named entity 'H1N1' named entity 'COVID' named entity 'endothelial activation' named entity 'SIRS' named entity 'post-mortem' named entity 'IL-1' named entity 'pyroptosis' named entity 'cardiomyocytes' named entity 'SARS-CoV-2' named entity 'capillary' named entity 'COVID' named entity 'lung' named entity 'CC-BY-ND' named entity 'TNF-alpha' named entity 'alveolar epithelial cells' named entity 'endothelial activation' named entity 'ICU' named entity 'interleukin' named entity 'immunohistochemical' named entity 'ICU' named entity 'endothelial dysfunction' named entity 'WHO' named entity 'preprint' named entity 'protein' named entity 'Control groups' named entity 'clone' named entity 'thrombotic' named entity 'preprint' named entity 'pyroptosis' named entity 'ICU' named entity 'NLRP3' named entity 'interferon-gamma' named entity 'medical records' named entity 'IL-1B' named entity 'SARS' named entity 'preprint' named entity 'IBM' named entity 'medRxiv' named entity 'COVID' named entity 'Brazil' named entity 'MERS-CoV' named entity 'H1N1' named entity 'cytokine storm' named entity 'endothelial cell' named entity 'thrombotic events' named entity 'pro-inflammatory' named entity 'inflammatory conditions' named entity 'glycocalyx' named entity 'viral proteins' named entity 'IL-1B' named entity 'medRxiv' named entity 'Curitiba' named entity 'statistical analysis' named entity 'lung' named entity 'DAD' named entity 'virus' named entity 'CD163' named entity 'Middle East respiratory syndrome coronavirus' named entity 'pyroptosis' named entity 'platelet adhesion' named entity 'immunohistochemical techniques' named entity 'Minimally invasive' named entity 'ICAM-1'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software